1 The in vivo antiatherogenic activity of the calcium antagonist lercanidipine and its (R)-enantiomer was investigated in two dierent types of atherosclerotic lesions (hyperplastic and fatty-streak lesions) in rabbits. were given by subcutaneous injection for 10 weeks to White New Zealand rabbits, with cholesterol feeding beginning at week 2. The hyperplastic lesion was obtained by positioning a hollow silastic collar around one carotid artery, while aortic fatty streak lesions were induced by cholesterol feeding. In untreated animals (n=5), 14 days after collar positioning an intimal hyperplasia was clearly detectable: the arteries without collar showed a intima/media (I/M) ratio of 0.03+0.02, whereas in carotids with a collar the ratio was 2+0.42. In lercanidipine-treated animals a signi®cant and dose-dependent eect on intimal hyperplasia was observed. I/M ratios were 0.73+0.4, 0.42+0.1, 0.32+0.1 for 0.3, 1, and 3 mg kg 71 week
Introduction
With the increasing knowledge on the pathogenesis of atherosclerosis it appears that prevention of cardiovascular disease will involve not only the correction of risk factors such as dyslipidemia or elevated arterial blood pressure but also the direct pharmacological control of atherogenic processes occurring in the arterial wall (Ross, 1993) . While the former approach is now de®nitely accepted in man, the latter still represents a`therapeutic hope' which requires experimental and clinical con®rmation. Recently, a great eort has been made in evaluating the direct eect of drug therapy on the arterial wall (Jackson & Schwartz, 1992) . Abnormalities or dysfunctions of the endothelial cells can favour vascular smooth muscle cell migration from the media and proliferation within the intima, and increase lipid deposition or reduce lipid clearance from in®ltrating monocytes. These processes trigger a cascade of events leading to the development of vascular disease (Ross, 1993; Jackson & Schwartz, 1992; Popma et al., 1991) .
Therapeutic interventions which interfere with early stages of atherosclerosis may improve chances of halting or slowing the progression of the diseases. Among drugs currently available for therapy of vascular diseases, calcium antagonists have been investigated extensively experimentally as antiatherogenic agents in a variety of in vitro (Bernini et al., 1989 (Bernini et al., , 1993a Lichtor et al., 1989) and in vivo (Bernini et al., 1989; Jackson & Schwartz, 1992; Henry, 1990 ) experimental models. In in vivo models calcium antagonists protect against lesions induced by cholesterol feeding, endothelial injury, and experimental calcinosis (Bernini et al., 1989; Keogh & Schroeder, 1990; Weinstein & Heider, 1989; Catapano et al., 1988) . The in vitro eects of these drugs on processes which play a role in the development of atherosclerotic lesions might help in explaining these results (Bernini et al., 1989; Catapano et al., 1988; Lichtor et al., 1989) . For instance, several calcium antagonists inhibit the migration of smooth muscle cells (SMC) (Nomoto et al., 1988) , the uptake of lipids by macrophages (Daugherty et al., 1987; Bernini et al., 1991; Schmitz et al., 1988; Stein & Stein, 1987) , and the production of collagen, elastin, and proteoglycans (Waters et al., 1990) and in several in vivo experiments the`antiatherosclerotic' properties of Ca 2+ antagonists have been substantiated (Catapano, 1997) . The question whether these eects can be extrapolated to human being however is still unsolved and studies on the bene®cial eects of Ca 2+ antagonist on myocardial infarction morbility and mortality are so far negative (Cleland & Krikler, 1993) .
Whether the eects of calcium antagonist on experimental atherosclerosis are linked to the action on the L-type channel block still remains unclear. However, few attempts have been made to relate these in vitro eects to the complex changes which occur in the vessel wall. Recently, a model of carotid neointimal hyperplasia, mainly dependent on SMC migration and proliferation, has been developed (Soma et al., 1993 (Soma et al., , 1995 . Lercanidipine, a new dihydropyridine calcium antagonist, presents with a chiral centre that produces two enantiomers. The (R)-enantiomer is about 2 ± 3 orders of magnitude less eective as a ligand to the calcium channel and in lowering blood pressure, thus oering a unique opportunity to evaluate whether Ca 2+ antagonism plays a role in determining the antiatherosclerotic activity of the 1,4-dihydropyridine calcium antagonists. Lercanidipine has been shown to eectively reduce smooth muscle cell proliferation in vitro (Corsini et al., 1996) and to be an eective antioxidant for low density lipoprotein (LDL) both in copper and endothelial cell mediated oxidation (Catapano et al., manuscript in preparation) .
Using this model in cholesterol-fed rabbits we investigated the in vivo eect of lercanidipine, and its enantiomer, on two dierent vascular lesions: one mainly characterized by intimal SMC hyperplasia, induced by collar insertion around a carotid artery, and the other by lipid deposition in arterial macrophages (aortic fatty-streak lesion), induced by feeding the animals with a cholesterol-rich diet.
Methods
New Zealand male rabbits (n=100) (2 ± 2.5 kg, Charles River, Calco, Italy) were used in this study. Animals were divided into the following groups and maintained in identical experimental conditions: (1) control group (n=20): cholesterol-rich diet; (2) low dose lercanidipine-treated group (n=20): cholesterol-rich diet+lercanidipine 0. ). All animals received a daily cholesterol supplement for 8 weeks after a 2 week period of subcutaneous, once a week, pretreatment with the indicated doses of the drug. The daily doses of cholesterol (1.6 g) were given in the morning (at 08.00 h) each mixed in 20 g of food pellets. Normal chow, up to 150 g, was added after all the cholesterol-rich diet was eaten (usually within 30 min). Lercanidipine and (R)-lercanidipine (hydrochloride salt, Recordati, Milano, Italy) were administered subcutaneously as solutions in 50% propylene glycol. The doses of lercanidipine and its (R)-enantiomer utilized here did not aect arterial blood pressure, at the dose of 3 mg kg 71 week 71 . Systolic blood pressure was 95+3.5, 93+3.1, and 96+6.3 mm Hg 71 in controls, lercanidipine and (R) lercanidipine treated animals respectively after 24 h from the administration of the drug. Animals had free access to water and were kept in a 12 h light-dark cycle. Blood was drawn from the central ear artery at day 29 after treatment started in order to monitor the lercanidipine plasma level at 24 h postdose. A stereospeci®c analytical method was utilized (Farina et al., 1994) . The doses of lercanidipine used were determined from preliminary kinetic studies. In rabbits subcutaneous administration of lercanidipine 3 and 1 mg kg 71 resulted in plasma levels of 3.2 and 0.5 mg ml 71 , after 7 days from the administration.
Total serum cholesterol was measured by an enzymatic procedure (Catapano et al., 1988) , at collar insertion and sacri®ce. High density lipoprotein (HDL) cholesterol was determined by the same method after of very low density and low density lipoproteins (LDL) precipitation with phosphotungstic acid (Catapano et al., 1988) . At the end of the treatment the animals were sacri®ced by an overdose of sodium pentobarbital (65 mg kg 71 , i.v.).
Fatty streaks
Aortas were immediately retrieved, cleaned from blood and adherent tissue, and ®xed in buered formaldehyde (10%) for 24 h at 48C. Aortic lipids were stained with Sudan IV as previously described (Catapano et al., 1988) . The extension of aortic atherosclerotic plaques, determined as Sudan stainable areas, was measured by planimetry by two independent operators and expressed as per cent of the aorta inner surface covered by plaques. Data are the means of two evaluations, the coecient of variation was less than 5%.
Intimal hyperplasia
Intimal hyperplasia was mechanically induced by a silastic collar (Dupont, Milano, Italy) placed around one carotid artery of ®ve separate rabbits from each group, 6 weeks after dietary treatment started. Rabbits were anaesthetized by intramuscular injection of 5 mg kg 71 xylazine and 35 mg kg 71 ketamine. Animals were then placed in dorsal recumbency. A neck midline incision was made and both carotid arteries were surgically exposed. A non occlusive, biologically inert, soft, and hollow silastic 1 collar was positioned around both carotids. The collar was 1.5 cm in length and touched the artery circumference at two points 1 cm apart. In the sham arteries the collar was removed just before carotids were repositioned and the wounds were sutured. Animals were sacri®ced 2 weeks after the collar placement. All animals were given a lethal dose of sodium pentobarbital, and the vasculature was perfused with 0.1 mol l 71 phosphate-buffered-saline (PBS) for 10 min. Animals were then perfusion®xed for another 20 min with 3% glutaraldehyde buered with 0.1 mol l 71 PBS at a pressure of 100 mm Hg 71 (Soma et al., 1993 (Soma et al., , 1995 . Both carotid arteries were retrieved, paran embedded and stained with hematoxylin/eosin. At least 600 cross sections (5 mm) were cut for each artery. Intimal thickness formation was measured by light microscopy and expressed as the ratio between the cross-sectional thickness of intimal and medial tissue. Intima/media (I/M) ratios were calculated to normalize the data. The value of I/M obtained from each animal is the mean of at least 120 measurements performed on at least 60 sections (Soma et al., 1993 (Soma et al., , 1995 .
Cell proliferation assay
Proliferation index was assessed by injecting collared rabbits with 5-bromo-2'-deoxyuridine (BrdU) (40 mg kg 71 , i.v.), 3 h before sacri®ce. BrdU incorporation was revealed by using a monoclonal antibody antiBrdU (dilution 1 : 100), after a DNA denaturation with in 2N HCl, a buering with Na 2 B 4 O 7 and a digestion with pepsin 0.05% in 20 mM HCl at 378C for 20 min in PFA-®xed samples. All nuclei were stained with the DNA intercalating dye Hoechst 33528 1 mg ml 71 in PBS and labelling index (LI) was calculated as the per cent of BrdUpositive vs total nuclei.
Image analysis system
Total and BrdU-positive cells and the cross-sectional thickness of the intima and underlying media were analysed by an image analysis system interfaced to a Zeiss Axioscope microscope. The image-analysis system consisted of a Macintosh IIx computer (Apple) equipped with a Frame Grabber Card (QuickCapture, Data Translation), a Sony high-resolution video camera, and a Trinitron SuperMac 21-in colour monitor. All measurements were performed using National Institutes of Health Software Image, version 1.47 (Dr Wayne Rasband, NIH, Bethesda, MD, U.S.A.).
Statistics
Group data are expressed as means+s.d. Statistical comparison of all numerical data between groups were performed by ANOVA. A P value 50.05 was taken as statistically signi®cant. Where statistically signi®cant dierences were established between groups further comparison for homogeneity means was made by using a post hoc Duncan's multiple range test. All statistical calculations were performed by CSS Software (Statsoft, U.S.A.).
Results
Of the animals included in the study ®ve died (two in the cholesterol-fed group, one in the lercanidipine 0. , two lercanidipine 3 mg kg 71 week 71 ). Records of food intake did not show any signi®cant dierence among the groups or within the groups. There were no signi®cant dierences in the baseline body weight and serum cholesterol values between the groups of animals examined. Serum cholesterol values increased with cholesterol feeding in a time-dependent manner. Lercanidipine had no signi®cant eect on serum total cholesterol levels (Tables 1 and  2) , and HDL cholesterol and body weight (from 2.8 ± 3.0 kg in the dierent groups). Exposure of the animals to lercanidipine was con®rmed by the plasma levels of the drug (Table 3) . The enantioselective method used showed that plasma concentration of lercanidipine enantiomers increased linearly with the dose in the range tested.
Eect of lercanidipine on fatty streaks
Upon cholesterol feeding the area of the aorta covered by plaques was 27+13% (Table 1 ). Lercanidipine at the doses of 0.3 and 1 mg kg 71 week 71 did not reduce the plaque area (23+17% and 19+12%, respectively, P=n.s.). At a dose of 3 mg kg 71 week 71 , however, lercanidipine eectively reduced the lesion area by 40% to 16+9 (P50.01). The (R)-enantiomer (3 mg kg 71 week 71 ) showed eects similar to those of the high dose lercanidipine (17+9%, P50.01). When three dierent areas of the aorta were evaluated the eect of the treatment was clearly detectable in the thoracic and abdominal segments with a clear dose-response eect (Table  1 ). The high dose of the enantiomer was as eective as the high dose lercanidipine. No statistically signi®cant eects were observed in the arch of the aorta, after treatment either with lercanidipine or its (R)-enantiomer. 
Eect of lercanidipine on collar-induced intimal hyperplasia
In the control group a marked increase in intimal thickness was evident in the carotids with collar (Table 2 and Figure 1 ), whereas the sham-operated arteries did not show thickening of the intima either in positive control or drug-treated rabbits. The mean value of the I/M ratio in the collared arteries of the control group (n=5) was more than 60 fold greater (2+0.42) than in the sham group (n=20) (0.03+0.02). The media thickness was not aected either by the positioning of the collar nor by lercanidipine treatment (151+11 mm in the sham carotid, vs 147+12 mm in cholesterol-fed animals and 156+13 mm in the lercanidipine treated animals, n=5, P=n.s.).
The intimal hyperplasia was mostly cellular but extracellular matrix and lipid deposition were also present. Light microscopic observation of the sham tissue con®rmed the absence of intimal hyperplasia or lipid deposits in spite of the severe hypercholesterolemia in these animals. Lercanidipine, at all doses, reduced the I/M ratio dose-dependently when compared with the control-group. Dierences versus the control were statistically signi®cant at all doses including the 3 mg kg 71 week 71 of the (R)-enantiomer (Table 2 and Figure  1 ). In animals treated with lercanidipine the inhibitory eect on intimal hyperplasia consisted of fewer layers of cells ( Figure  1) . As for cholesterol feeding, lercanidipine or its enantiomer had no eect on the media thickness of the carotid artery, therefore the eect of the drug on the ratio is due to a reduction of the intimal thickness.
Cell speci®c antibodies were used to evaluate the composition of intimal and medial cell population in carotid arteries with and without collar by immunostaining techniques. The medial tissue of sham-operated arteries and collar-applied arteries of all animals showed a strong reactivity for a-smooth muscle (SM)-actin-positive cells (Figure 2a ). The lesion induced by collar positioning contained predominantly a-SM actin-positive cells (490% of the whole cell population) (Figure 2a) . Also a few macrophages, indenti®ed by a positive reaction with the speci®c antibody RAM11 (Figure 2b) were detected in the lesion but not in the media. Direct in vivo evaluation of cell proliferation was performed by measuring the incorporation of BrdU, a thymidine analogue, into replicating DNA. Double-immuno¯uorescence labelling techniques indicates that at any time point more than 95% of the BrdU-positive cells were smooth muscle cells. An average of 7% of total cells in control animals were BrdU-positive ( Figure  2c and Table 2 ). Pretreatment with lercanidipine racemate resulted in a signi®cant dose-dependent inhibition of smooth muscle cell proliferation ( Table 2 ). The (R)-enantiomer (3 mg kg 71 week 71 ) showed eects similar to those of the high dose lercanidipine (Table 2) .
Discussion
The increasing knowledge on the pathogenesis of atherosclerosis has prompted investigations into the possibility of direct pharmacological control of the pathological processes occurring in the arterial wall. Calcium antagonists are well established in the treatment of a number of cardiovascular disorders (Nayler, 1993; Waters & Lesperance, 1994) . There are three subclasses of calcium channel antagonists: the phenylalkylamine derivatives (e.g., verapamil), the benzothiazepines (e.g., diltiazem), and the dihydropyridines (e.g., nifedipine). All three subclasses modify calcium entry into cells by interacting with speci®c binding sites on the a 1 subunit of the L-type voltage-dependent calcium channel (Nayler, 1993) . The short-acting dihydropyridines, such as nifedipine, should be used with caution for long-term therapy since they have been reported to increase the incidence of acute coronary events. This is not the case for verapamil, diltiazem, or longacting dihydropyridines such as lercanidipine.
Besides evidence that calcium antagonists reduce blood pressure, experimental and clinical data support the concept that Ca 2+ antagonists may protect against structural changes occurring in the vessel wall during the progression of atherosclerosis (Jackson & Schwartz, 1992; Nayler, 1992; Lichtlen et al., 1987; Parmley, 1987) . Several calciumdependent processes contribute to atherogenesis, including lipid in®ltration and oxidation, endothelial injury, chemotactic and growth factor activities, smooth muscle cell migration and proliferation (Nayler, 1993; Catapano, 1997) .
Calcium antagonists modulate LDL cholesterol metabolism (Bernini & Allorio, 1988) and aect SMC migration and proliferation in vitro (Jackson & Schwartz, 1992; Nomoto et al., 1988; Corsini et al., 1993 Corsini et al., , 1994 . Several Ca 2+ antagonists eectively reduce the extent of fatty-streak lesion in animals fed a cholesterol-rich diet by interfering with cholesterol esteri®cation (Bernini et al., 1993b) . However, fewer data are available on the eect of calcium antagonists on intimal hyperplasia due to SMC cell migration and proliferation (Jackson & Schwartz, 1992; Soma et al., 1996) . Lercanidipine has been shown in vitro to interfere with SMC cell proliferation and migration (Corsini et al., 1996) , to modulate acyl cholesterol acyl transferase activity (Bernini et al., personal communication) and to act as antioxidant for LDL in copper and endothelial cell-mediated oxidation (Catapano et al., manuscript in preparation) .
In this study we aimed at addressing whether lercanidipine, a dihydropyridine calcium antagonist, could aect two dierent types of atherosclerotic lesions. The aortic fattystreak lesions induced by cholesterol feeding are mainly due to lipid accumulation by macrophages, while the predominant cell type in cued-carotid arteries are SMC with scarce macrophages (Figure 2a,b) (Soma et al., 1993 (Soma et al., , 1995 (Soma et al., , 1996 . The mechanisms by which the latter lesion is induced are matter of debate. Among many in¯ammatory responses, changes in blood¯ow velocity, loss of perivascular innervation, kinking of the artery have been advocated (De Meyer et al., 1997) . Thus, it is possible to investigate in the same animal the eect of a drug on two dierent types of lesions, a fattystreak lesion versus an intimal hyperplastic lesion. Lercanidipine eectively reduced the extent of fatty lesions in a dosedependent manner and the eect was particularly clear in the abdominal and thoracic aorta ( Table 1) . The fact that, in analogy with other 1,4-DHPs (Catapano, 1992 (Catapano, , 1997 , no signi®cant eect was noted in the arch, might relate to the fact that the extent of lesions is too large to be aected by the treatment. Alternatively one could speculate that the surface area covered by lesions is not aected while the thickness of the lesions is reduced. Our evaluation procedure does not allow detection of this eect.
Lercanidipine also inhibited in a dose-dependent manner the hyperplasia acutely induced in carotid of hypercholesterolemic rabbits; at doses as low as 0.3 mg kg 71 week 71 lercanidipine inhibited intimal hyperplasia by about 60%. Notably, the hyperplasia in hypercholesterolemic rabbits was greater than that observed in normocholesterolemic animal (Soma et al., 1993) suggesting a detrimental eect of hypercholesterolemia on this lesion. The mechanisms responsible for the inhibitory eect of lercanidipine and its (R)-enantiomer on the development of intimal lesions demonstrated here remains to be clari®ed. The systemic exposure of wall tissues to both the racemate and (R)-enantiomer greatly reduced active DNA synthesis of the smooth muscle cells, indicating an eect on myocyte proliferation (Table 2 and Figure 2c ). An eect on smooth muscle cell migration cannot be excluded. This is in contrast with the results by U È stuÈ nes et al. (1996) who recently observed no eect on intimal thickening by verapamil in normolipidemic rabbits. The apparent discrepancy could depend on at least two reasons: (a) as reported for clinical eects, the relative speci®city of calcium antagonists from dierent classes stems from the fact that each class has a unique binding site on the a 1 calcium channel subunit; (b) the antiproliferative eect shown by lercanidipine in this study may be mediated by its antioxidant properties. Lercanidipine, in fact, possesses antioxidant properties in vitro, protecting LDL from oxidative modi®ca-tion (Catapano et al., manuscript in preparation) ; (c) the presence of hypercholesterolemia determines the response to lercanidipine. The latter possibility is unlikely since preliminary data from our laboratory in normocholesterolemic animals indicate that lercanidipine and its enantiomer eectively reduce the intima/media ratio in the carotid. Several in vivo studies with antioxidants (including probucol and vitamin E) indicate that these compounds eectively reduce the extent of fatty-streak lesions in aortas of cholesterol-fed and Watanabe rabbits (Kita et al., 1987; Carew et al., 1987; Daugherty et al., 1989; Erikson et al., 1988) . Furthermore, lercanidipine directly aects intracellular cholesterol homeostasis by inhibiting cholesterol esteri®cation in macrophages, an eect resulting in a decreased cellular accumulation of cholesteryl esters (Bernini et al., 1993b; Soma et al., 1994) . Finally, the results on the hyperplastic lesions strongly support the in vitro observation that lercanidipine can aect directly SMC cell migration and/or proliferation (Corsini et al., 1996) , a property shared with other calcium antagonists (Bernini et al., 1993b; Soma et al., 1994) .
Overall, in this model, hyperplasia of the intima appeared to be more sensitive to lercanidipine than fatty-streak lesions. We do not have an explanation for this dierential eect but one possibility could be a dierent sensitivity of the mechanisms underlying the two dierent types of lesion to lercanidipine: cholesterol homeostasis by macrophages for the fatty lesion and SMC migration and/or proliferation for the intimal hyperplasia. In vitro the inhibition of cholesterol esteri®cation in macrophages required in fact concentrations higher than those necessary to inhibit SMC proliferation (Corsini et al., 1996) . Alternatively, lercanidipine might distribute dierently among areas of the vascular bed.
The eect of the lercanidipine (R)-enantiomer is of interest for two reasons: (1) the enantiomer shows at least two orders of magnitude lower anities than lercanidipine at the Ca 2+ channel (Leonardi et al., 1997) . This is an indication that the calcium antagonist activity might not be essential to the antiatherosclerotic activity, in agreement with the eect of the enantiomer at 3 mg kg 71 week 71 and to the fact that blood pressure was not lowered by either treatment; (2) the (R)-enantiomer shares antioxidant properties with the racemate. The latter may contribute, at least in part, to the antiatherosclerotic activity, since it is known that several antioxidants are eective in reducing atherosclerotic lesions in cholesterol-fedrabbits (Kita et al., 1987; Carew et al., 1987; Soma et al., 1996) . Whether the eects on fatty streaks and intimal hyperplasia are linked to the antioxidant activity of lercanidipine or to other properties, however, remains to be addressed.
In conclusion the present in vivo ®ndings show that lercanidipine possesses antiatherosclerotic activities at early stages of experimental atherosclerosis that appear to be independent of the Ca 2+ antagonist activity. This direct antiatherosclerotic activity of lercanidipine oers new therapeutic directions for this calcium antagonist, that require further studies to be fully understood and may pave the way to the use of antiatherosclerotic drugs not acting on risk factors but directly interfering with the early steps of atherosclerotic lesion formation.
